Table 2.
Univariable and multivariable analysis of OS in the VR group.
| Variables | Univariable analysis | Multivariable analysis | |
|---|---|---|---|
| P value | HR (95% CI) | P value | |
| Age, y (≤60/>60) | 0.971 | ||
| Sex (Male/Female) | 0.667 | ||
| Cirrhosis (yes/no) | 0.060 | ||
| Ascites (yes/no) | 0.144 | ||
| Splenomegaly (yes/no) | 0.007 | 1.340 (1.095-1.641) | 0.005 |
| ICGR 15 (≤10%/>10%) | 0.751 | ||
| Tumor capsule (yes/no) | 0.151 | ||
|
Up-to-seven criteria
(beyond/within) |
0.002 | 1.298 (1.048-1.607) | 0.017 |
| AFP, ug/L (≤20/>20) | 0.030 | ||
| GGT, u/L (≤50/>50) | 0.956 | ||
| AST, u/L (≤40/>40) | 0.700 | ||
| ALT, u/L (≤40/>40) | 0.511 | ||
| Albumin, g/L (≤30/>30) | 0.158 | ||
| TBIL, umol/L (>20.5/≤20.5) | 0.049 | 1.505 (1.104-2.052) | 0.010 |
| PT, sec (≤14/>14) | 0.431 | ||
| WBC, 109/L (≤4/>4) | 0.771 | ||
| HB, g/L (≤120/>120) | 0.626 | ||
| Platelet count, 109/L (≤100/>100) | 0.019 | 1.326 (1.088-1.617) | 0.005 |
| Sorafenib after TACE (yes/no) | <0.001 | 0.605 (0.494-0.742) | <0.001 |
| Radical therapy after TACE (yes/no) | 0.606 | ||
CI, confidence interval; HR, hazard ratio; OS, overall survival.